388 related articles for article (PubMed ID: 33742979)
1. Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy.
Kuusk T; Abu-Ghanem Y; Mumtaz F; Powles T; Bex A
Curr Opin Urol; 2021 May; 31(3):262-269. PubMed ID: 33742979
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma.
Kuusk T; Bex A
Hematol Oncol Clin North Am; 2023 Oct; 37(5):907-920. PubMed ID: 37369611
[TBL] [Abstract][Full Text] [Related]
3. A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality.
Palumbo C; Mazzone E; Mistretta FA; Knipper S; Perrotte P; Shariat SF; Saad F; Kapoor A; Lattouf JB; Simeone C; Briganti A; Antonelli A; Karakiewicz PI
Clin Genitourin Cancer; 2020 Aug; 18(4):314-321.e1. PubMed ID: 32482565
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma: A Review.
Ghoreifi A; Vaishampayan U; Yin M; Psutka SP; Djaladat H
JAMA Oncol; 2024 Feb; 10(2):240-248. PubMed ID: 38095885
[TBL] [Abstract][Full Text] [Related]
5. Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials.
Marconi L; Sun M; Beisland C; Klatte T; Ljungberg B; Stewart GD; Dabestani S; Choueiri TK; Bex A
Clin Genitourin Cancer; 2021 Apr; 19(2):e92-e99. PubMed ID: 33526329
[TBL] [Abstract][Full Text] [Related]
6. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study.
Yip W; Ghoreifi A; Gerald T; Lee R; Howard J; Asghar A; Khanna A; Cai J; Aron M; Gill I; Thompson RH; Uzzo R; Margulis V; Singla N; Djaladat H
Eur Urol Oncol; 2023 Dec; 6(6):604-610. PubMed ID: 37005212
[TBL] [Abstract][Full Text] [Related]
7. [DEFERRED NEPHRECTOMY IN A PATIENT WITH METASTATIC RENAL CELL CARCINOMA AFTER A NEAR-COMPLETE RESPONSE TO IMMUNOTHERAPY].
Purim O; Raz O; Eisner A; Baram N; Leonov Polak M; Rybo L
Harefuah; 2022 Dec; 161(12):763-768. PubMed ID: 36916116
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.
Flippot R; Escudier B; Albiges L
Drugs; 2018 Sep; 78(14):1443-1457. PubMed ID: 30187355
[TBL] [Abstract][Full Text] [Related]
9. Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
Yanagisawa T; Schmidinger M; Kawada T; Bekku K; Kimura T; Shariat SF
Eur Urol Focus; 2023 Mar; 9(2):275-277. PubMed ID: 36775716
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
11. Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy.
Carlo MI; Attalla K; Mazaheri Y; Gupta S; Yildirim O; Murray SJ; Coskey DT; Kotecha R; Lee CH; Feldman DR; Russo P; Patil S; Motzer RJ; Coleman JA; Durack JC; Chen YB; Akin O; Ari Hakimi A; Voss MH
Eur Urol; 2022 Jun; 81(6):570-573. PubMed ID: 35183395
[TBL] [Abstract][Full Text] [Related]
12. RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.
Oza B; Frangou E; Smith B; Bryant H; Kaplan R; Choodari-Oskooei B; Powles T; Stewart GD; Albiges L; Bex A; Choueiri TK; Davis ID; Eisen T; Fielding A; Harrison D; McWhirter A; Mulhere S; Nathan P; Rini B; Ritchie A; Scovell S; Shakeshaft C; Stockler MR; Thorogood N; Parmar MKB; Larkin J; Meade A
Contemp Clin Trials; 2021 Sep; 108():106482. PubMed ID: 34538402
[TBL] [Abstract][Full Text] [Related]
13. Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial.
Motzer RJ; Russo P; Grünwald V; Tomita Y; Zurawski B; Parikh O; Buti S; Barthélémy P; Goh JC; Ye D; Lingua A; Lattouf JB; Albigès L; George S; Shuch B; Sosman J; Staehler M; Vázquez Estévez S; Simsek B; Spiridigliozzi J; Chudnovsky A; Bex A
Target Oncol; 2023 Sep; 18(5):639-641. PubMed ID: 37659025
[TBL] [Abstract][Full Text] [Related]
14. Is cytoreductive nephrectomy relevant in the immunotherapy era?
Singla N; Ghandour RA; Margulis V
Curr Opin Urol; 2019 Sep; 29(5):526-530. PubMed ID: 31305273
[TBL] [Abstract][Full Text] [Related]
15. BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer.
Epaillard N; Simonaggio A; Elaidi R; Azzouz F; Braychenko E; Thibault C; Sun CM; Moreira M; Oudard S; Vano YA
Bull Cancer; 2020 Jun; 107(5S):eS22-eS27. PubMed ID: 32620212
[TBL] [Abstract][Full Text] [Related]
16. The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol.
Ursprung S; Mossop H; Gallagher FA; Sala E; Skells R; Sipple JAN; Mitchell TJ; Chhabra A; Fife K; Matakidou A; Young G; Walker A; Thomas MG; Ortuzar MC; Sullivan M; Protheroe A; Oades G; Venugopal B; Warren AY; Stone J; Eisen T; Wason J; Welsh SJ; Stewart GD
BMC Cancer; 2021 Nov; 21(1):1238. PubMed ID: 34794412
[TBL] [Abstract][Full Text] [Related]
17. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Jpn J Clin Oncol; 2021 Feb; 51(2):296-304. PubMed ID: 32989464
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors for BCG-resistant NMIBC: the dawn of a new era.
Albisinni S; Martinez Chanza N; Aoun F; Diamand R; Mjaess G; Azzo JM; Esperto F; Bellmunt J; Roumeguère T; DE Nunzio C
Minerva Urol Nephrol; 2021 Jun; 73(3):292-298. PubMed ID: 33781027
[TBL] [Abstract][Full Text] [Related]
20. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients.
Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L
Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
